AAM
RXRX icon

Advisors Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Advisors Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118,117
Closed -$363K – 1483
2026
Q1 		$363K Sell
118,117
-17,788
-13% -$68.7K 0.01% 1037
2025
Q4 		$556K Sell
135,905
-1,067
-0.8% -$5.29K 0.01% 921
2025
Q3 		$668K Sell
136,972
-1,850
-1% -$9.71K 0.01% 905
2025
Q2 		$702K Buy
138,822
+5,337
+4% +$26.2K 0.01% 876
2025
Q1 		$706K Buy
133,485
+117,851
+754% +$859K 0.01% 853
2024
Q4 		$106K Buy
+15,634
New +$105K ﹤0.01% 1218

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Advisors Asset Management's RXRX Position: Q2 2026 in Review

Advisors Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 118,117 shares — an estimated $363K sold.

Advisors Asset Management first reported a position in RXRX in Q4 2024 and held it in 6 quarters. The position peaked at $706K in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Advisors Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Advisors Asset Management sold 118,117 Recursion Pharmaceuticals shares in Q2 2026, an estimated $363K.
  • Advisors Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Advisors Asset Management's Recursion Pharmaceuticals position peaked at $706K in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.